PI3K/mTOR Inhibitor-2 is primarily used in cancer research and therapy development due to its ability to target and inhibit the PI3K/AKT/mTOR signaling pathway, which is often dysregulated in various cancers. This compound is employed in preclinical studies to investigate its efficacy in suppressing tumor growth and proliferation by blocking key signaling molecules involved in cell survival and metabolism. It is also utilized in combination therapy studies to enhance the effectiveness of other anticancer agents. Additionally, PI3K/mTOR Inhibitor-2 serves as a valuable tool in understanding the molecular mechanisms of cancer progression and resistance to treatment, aiding in the development of targeted therapeutic strategies.